Navigation Links
GenVec Reports Fourth Quarter And 2012 Year-End Financial Results
Date:3/22/2013

nal Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the Company's RSV vaccine program.  This grant will be used to further advance the novel pediatric RSV vaccine.
 
  • Promising data were presented on GenVec's RSV vaccine program at the 8th Annual International Respiratory Syncytial Virus Symposium, demonstrating that GenVec's pre-clinical, universal RSV vaccine candidate is highly immunogenic and produces durable and broad protection from a single intramuscular administration.  Protection in cotton rat and mouse models was characterized by functional RSV neutralizing antibodies and no disease potentiation was observed.
     
  • Encouraging preclinical proof of concept data generated in non-human primates involving GenVec's RSV vaccine program were presented at the Keystone Symposia 2012 Meeting on Viral Immunity and Host Gene Influence.  GenVec's vaccine technology induced neutralizing antibody and significant T-cell responses with a single administration.  The immune responses were consistent with protective responses without disease potentiation, and multiple administrations increased the neutralizing antibody responses.
  • HSV Vaccine

  • GenVec conducted a successful pre-IND interaction with the U.S. Food and Drug Administration (FDA) to obtain guidance on the development plan for its vaccine against herpes simplex virus (HSV).  The outcome of the pre-IND interaction was obtaining clarification on the nonclinical, clinical, and chemistry, manufacturing, and control (CMC) requirements that need to be met in order to submit an acceptable IND.
  • Data were presented on GenVec's HSV vaccine program at the Keystone Symposia meeting on Immunological Mechanisms of Vaccination.  The Company disclosed that a single administration of its genetic vaccine was effective against HSV2 in two industry-accepted HSV disease models.
  • Mala
    '/>"/>

    SOURCE GenVec, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. GenVec To Release First Quarter 2012 Financial Results And Conduct A Conference Call On May 10, 2012
    2. GenVec Appoints Cynthia Collins as President and CEO
    3. GenVec Reports Inducement Award
    4. GenVec Announces Conditional Approval of FMD Vaccine for Cattle
    5. GenVec to Release Second Quarter 2012 Financial Results and Conduct a Conference Call on August 9, 2012
    6. GenVec Reports Second Quarter 2012 Financial Results
    7. GenVec Reports Third Quarter 2012 Financial Results
    8. GenVec to Present at 25th Annual ROTH Conference
    9. GenVec To Release Fourth Quarter And Year-end 2012 Financial Results And Conduct A Conference Call On March 22, 2013
    10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... , March 27, 2015 As of ... of incontinence devices for women. "Shipping ... most gratifying part is the hundreds of letters, ... whose lives have been positively impacted by our ... InControl. InControl recently released Apex, an ...
    (Date:3/27/2015)... 2015 RnRMarketResearch.com adds "Visceral ... research report of 52 pages with latest updates, ... library. The report "Visceral Pain - Pipeline Review, ... development for Visceral Pain, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ...
    (Date:3/26/2015)... - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), ... therapies for cardiovascular disease and overall health, announced that ... of the Corporation (the "Common Shares"). The Common Shares ... 5 th , 2014 to March 4 th , ... on or before April 1, 2015. Interest on the ...
    Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Visceral Pain Pipeline Review H1 2015 Market Research Report 2Visceral Pain Pipeline Review H1 2015 Market Research Report 3Visceral Pain Pipeline Review H1 2015 Market Research Report 4Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
    ... No-Cost, Noninvasive Tool Detects Risk for Undiagnosed Diabetes, ... Years, ALEXANDRIA, Va., April 28 A ... undiagnosed diabetes,identify whether they likely have the disease ... and complications associated with this now,epidemic illness, according ...
    ... Schering-Plough Corporation,(NYSE: SGP ) today reported ... ongoing Phase II study of boceprevir, its investigational ... with chronic,hepatitis C virus (HCV) genotype 1 were ... Association for the Study of the Liver (EASL). ...
    Cached Medicine Technology:Drug Combo Could Lower Diabetes Complications and Costs 2Drug Combo Could Lower Diabetes Complications and Costs 3Drug Combo Could Lower Diabetes Complications and Costs 4Drug Combo Could Lower Diabetes Complications and Costs 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9
    (Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 ... for patients with Type V AC joint injuries, according ... study, presented today at the American Orthopaedic Society for ... personnel returned to duty faster when surgery was not ... patients, with 7 receiving surgical treatment and 17 receiving ...
    (Date:3/28/2015)... Lately the student-athlete experience has undergone ... around the NCAA. In a March episode of ... a spectrum of universities and sports shed light on ... panel consists of athletes who have competed for universities ... and field, baseball, and volleyball. They discuss the value ...
    (Date:3/28/2015)... 2015 The "Petrick Sustainable Health ... health. After 18 years of research and experience with ... contenders, Dr. Jon Petrick is excited to be launching ... of the immediate benefits of this radical new system ... of strength of the immune system, faster healing of ...
    (Date:3/28/2015)... 28, 2015 Purity Products®, a ... announces the release of their revolutionary new weight ... two randomized, double-blind, placebo-controlled clinical studies to be ... hip size. MuffinStop™ is a combination of two ... mangostana, fused together to create one of the ...
    (Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
    Breaking Medicine News(10 mins):Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
    ... News) -- About half of the 30 million Americans ... about potential health risks before heading abroad, new research ... travelers departing the United States at Boston Logan International ... or middle-income nations. Only 54 percent of those travelers ...
    ... News) -- Older brothers are more likely than older sisters to ... at 195 children, aged 10 to 12, who had siblings that ... with older brothers were more likely to report being bullied at ... younger brother or sister. Older sisters were more likely to bully ...
    ... Chinese on EurekAlert! Chinese . BETHESDA, ... scientists and clinicians in the human genetics field will convene to ... Genetics 60th Annual Meeting, which will be held November 2-6, 2010, ... this year,s meeting will feature research on the application and use ...
    ... THURSDAY, Nov. 4 (HealthDay News) -- Annual screening for lung ... current or former heavy smokers by 20 percent, a major ... Americans who fall ill from lung cancer -- the nation,s ... could be significant, experts noted. And, unexpectedly, annual CT ...
    ... (Nov. 4, 2010) Nine years ago, scientists at ... occurring in the molecular makeup of the most aggressive ... they found that a specific protein called laminin-411 plays ... new blood vessels to support its growth and spread. ...
    ... Most mutations in the genes of the Salmonella ... And this is the case regardless whether they lead to ... by Uppsala University scientists in an article being published today ... have examined the impact of mutations on the rate of ...
    Cached Medicine News:Health News:Many U.S. Travelers Uninformed About Health Risks Abroad 2Health News:Studies validate use of family health history as gold standard in disease risk assessment 2Health News:Studies validate use of family health history as gold standard in disease risk assessment 3Health News:Studies validate use of family health history as gold standard in disease risk assessment 4Health News:Studies validate use of family health history as gold standard in disease risk assessment 5Health News:Studies validate use of family health history as gold standard in disease risk assessment 6Health News:Studies validate use of family health history as gold standard in disease risk assessment 7Health News:Studies validate use of family health history as gold standard in disease risk assessment 8Health News:Studies validate use of family health history as gold standard in disease risk assessment 9Health News:Studies validate use of family health history as gold standard in disease risk assessment 10Health News:Studies validate use of family health history as gold standard in disease risk assessment 11Health News:CT Scans Seem to Lower Lung Cancer Death Rates 2Health News:CT Scans Seem to Lower Lung Cancer Death Rates 3Health News:CT Scans Seem to Lower Lung Cancer Death Rates 4Health News:Cedars-Sinai 'nano-drug' hits brain-tumor target found in 2001 2Health News:Cedars-Sinai 'nano-drug' hits brain-tumor target found in 2001 3Health News:Unexpectedly small effects of mutations in bacteria bring new perspectives 2
    ... Clear Plus™ Uncuffed Endotracheal Tube w. FlexiSlip™ Stylet, ... use. A quality Rusch endotracheal tube with a ... you time and storage space. The stylet has ... It is designed with a soft distal tip ...
    ... stylet inside. Sterile, Latex Free, Single ... tube with a preloaded Slick® Stylet ... time and storage space. The stylet ... and has a stopper to help ...
    ... PVC. Murphy eye-nasal. High volume/low pressure ... For improved surgical access. Designed to ... incorporating a preformed curvature. Thin-walled, large ... adapts to the anatomical situation at ...
    Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. No cuff.Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Sterile...
    Medicine Products: